CAR T Study For Blockbuster Drug Granted Breakthrough Therapy Designation For Multiple Myeloma

A pharmaceutical sponsor needed help with a two-part, multisite Phase 1 study in adults with relapsed/refractory multiple myeloma. Specifically, the sponsor was looking for a team with CAR T experience, and a system that could handle their unique database built. In addition, the sponsor also required a team that could provide in-house data management, as well as a biostatistical team.

Discover how the company was able to overcome prior vendor relationship frustrations and receive support for a database build of EDC and IRT, as well as get aid with data management and biostatistics.